Top

Translational Neurodegeneration

Published in:

Open Access 01-12-2016 | Research

The predictive value of SS-16 in clinically diagnosed Parkinson’s disease patients: comparison with ^99mTc-TRODAT-1 SPECT scans

Authors: Wenyan Kang, Fangyi Dong, Dunhui Li, Thomas J. Quinn, Shengdi Chen, Jun Liu

Published in: Translational Neurodegeneration | Issue 1/2016

Abstract

Background

Dopamine transporter based imaging has high diagnostic performance in distinguishing patients with Parkinson’s disease (PD) from patients with non-Parkinsonian syndromes. Our previous study indicated that the “Sniffin’ Sticks” odor identification test (SS-16) acts as a valid instrument for olfactory assessment in Chinese PD patients. The aim of the study was to compare the efficacy of the two methods in diagnosing PD.

Methods

Fifty-two PD patients were involved in this study and underwent single photon emission computed tomography (SPECT) imaging using the labeled dopamine transporter radiotracer ^99mTc-TRODAT-1 to assess nigrostriatal dopaminergic function. Olfactory function was assessed with the “Sniffin’ Sticks” odor identification test (SS-16) in all patients who received DAT-SPECT scanning. Statistical analysis (SPSS version 21) was carried out to determine the diagnostic accuracy of SS-16 as well as its correlation with ^99mTc-TRODAT-1 SPECT, its positive predictive value (PPV), and negative predictive value (NPV).

Results

We identified a negative correlation between SS-16 and DAT SPECT (Kappa = 0.269, p = 0.004). By using the ^99mTc-TRODAT-1 uptake results as the gold standard, the sensitivity and specificity of SS-16 was 56.8 and 37.5 %, respectively. Furthermore, the negative and positive predictive values were calculated as 13.6 and 83.3 %, respectively.

Conclusions

SS-16 would not be used as a diagnostic tool for early stage PD patients. Negative results of SS-16 would not exclude the diagnosis of PD. Further tests are needed for validation.

Silveira-Moriyama L, Carvalho Mde J, Katzenschlager R, Petrie A, Ranvaud R, Barbosa ER, Lees AJ. The use of smell identification tests in the diagnosis of Parkinson’s disease in Brazil. Mov Disord. 2008;23(16):2328–34. doi:10.1002/mds.22241.CrossRefPubMed

Chen W, Chen S, Kang WY, Li B, Xu ZM, Xiao Q, Liu J, Wang Y, Wang G, Chen SD. Application of odoridentifycation test in Parkinson’s disease in China: a matched case-control study. J Neurol Sci. 2012;316(1–2):47–50. doi:10.1016/j.jns.2012.01.033.CrossRefPubMed

Fang YH, Chiu SC, Lu CS, Yen TC, Weng YH. Fully automated quantification of the Striatal uptake ratio of [(99m)Tc]-TRODAT with SPECTImaging: Evaluation of the diagnostic performance in Parkinson’s disease and the temporal regression of Striatal tracer uptake. Biomed Res Int. 2015;2015:461625. doi:10.1155/2015/461625.PubMedPubMedCentral

Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNM MI Res. 2015;5:12. doi:10.1186/s13550-015-0087–1.CrossRef

Bajaj N, Hauser RA, Seibyl J, Kupsch A, Plotkin M, Chen C, Grachev ID. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane I 123 injection (DaTSCANTM) in subjects with clinically uncertain parkinsonian syndromes. Alzheimers Res Ther. 2014;6(5–8):67. doi:10.1186/s13195-014-0067–0.CrossRefPubMedPubMedCentral

Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, Oertel W, Tolosa E, Lees AJ, Poewe W. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord. 2007;22(9):1229–38. Review.CrossRefPubMed

Hugh SC, Siu J, Hummel T, Forte V, Campisi P, Papsin BC, Propst EJ. Olfactory testing in children using objective tools: comparison of Sniffin’ Sticks and University of Pennsylvania Smell Identific ation Test (UPSIT). Otolaryngol Head Neck Surg. 2015;44:10. doi:10.1186/s40463-015-0061-y.CrossRef

Li DH, Zhang LY, Hu YY, Jiang XF, Zhou HY, Yang Q, Kang WY, Liu J, Chen SD. Transcranial sonography of the substantia nigra and its correlation with DAT-SPECT in the diagnosis of Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(8):923–8. doi:10.1016/j.parkreldis.CrossRefPubMed

Tolosa E, Borght TV, Moreno E. DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an openlabel study. Mov Disord. 2007;22(16):2346–51.CrossRefPubMed

10.

Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013;20:16–34. doi:10.1111/ene.12022.CrossRefPubMed

11.

Ubeda-Bañon I, Saiz-Sanchez D, de la Rosa-Prieto C, Martinez-Marcos A. α-Synuclein in the olfactory system in Parkinson’s disease: role of neural connections on spreading pathology. Brain Struct Funct. 2014;219(5):1513–26. doi:10.1007/s00429-013-0651-2.PubMed

12.

Wang J, Eslinger PJ, Smith MB, Yang QX. Functional magnetic resonance imaging study of human olfaction and normal aging. J Gerontol A Biol Sci Med Sci. 2005;60:510–4.CrossRefPubMed

13.

Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. PARS Investigators. Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study. Neurology. 2014;83(19):1739–46. doi:10.1212/WNL.0000000000000960.CrossRefPubMedPubMedCentral

14.

Burke WJ. Association of anosmia with autonomic failure in Parkinson disease.Comment on. Neurology. 2010;74(3):245–51. doi:10.1212/WNL.0b013e3181e793fa.CrossRef

15.

Müller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson’s disease: results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm. 2002;109:805–11.CrossRefPubMed

16.

Rodríguez-Violante M, Gonzalez-Latapi P, Camacho-Ordoñez A, Martínez-Ramírez D, Morales-Briceño H, Cervantes-Arriaga A. Comparing the accuracy of different smell identification tests in Parkinson’s disease: relevance of cultural aspects. Clin Neurol Neurosurg. 2014;123:9–14. doi:10.1016/j.clineuro.2014.04.030.CrossRefPubMed

17.

Menéndez-González M, Tavares F, Zeidan N, Salas-Pacheco JM, Arias-Carrión O. Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. Front Aging Neurosci. 2014;6:56. doi:10.3389/fnagi.2014.00056.PubMedPubMedCentral

Title: The predictive value of SS-16 in clinically diagnosed Parkinson’s disease patients: comparison with 99mTc-TRODAT-1 SPECT scans
Authors: Wenyan Kang
Fangyi Dong
Dunhui Li
Thomas J. Quinn
Shengdi Chen
Jun Liu
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Translational Neurodegeneration / Issue 1/2016
Electronic ISSN: 2047-9158
DOI: https://doi.org/10.1186/s40035-016-0062-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The predictive value of SS-16 in clinically diagnosed Parkinson’s disease patients: comparison with ^99mTc-TRODAT-1 SPECT scans

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

A survey of impulse control disorders in Parkinson’s disease patients in Shanghai area and literature review

The biomarkers of immune dysregulation and inflammation response in Parkinson disease

The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ

Benign tremulous Parkinsonism: a unique entity or another facet of Parkinson’s disease?

Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease

miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study